Indoco Remedies’ Goa Facility Secures EU GMP Certification, Bolstering Global Pharmaceutical Footprint

In the highly regulated world of pharmaceuticals, a stamp of approval from an international authority is more than just a formality; it’s a testament to unwavering quality and a passport to global markets. Indoco Remedies Limited recently announced a significant achievement that underscores its commitment to these very principles: its Goa manufacturing facility has successfully cleared an audit by the Malta Medicines Authority, earning the coveted EU Good Manufacturing Practice (GMP) certification.The inspection, conducted from November 19-24, 2025, focused on Indoco’s Plant I, responsible for solid oral dosage forms. This EU GMP certification confirms that the facility adheres to the stringent quality requirements outlined in the EC Directive, opening doors or strengthening Indoco’s presence in the crucial European market. This is a monumental validation for any pharmaceutical company, signifying that its manufacturing processes, facilities, and controls consistently meet the highest international standards.

Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd., emphasized the company’s core philosophy, stating, “Compliance is a core value that drives our quality systems. This approval reinforces our commitment to delivering the highest quality healthcare to our customers worldwide.” Indeed, such a certification not only enhances market access but also builds immense trust among global partners and patients alike.

Indoco Remedies: A Global Player

With this latest achievement, Indoco Remedies further solidifies its position as a research-oriented pharmaceutical company with a robust global presence.

• Annual Turnover: US$ 175 million
• Global Workforce: Over 6,000 employees, including 300+ scientists
• Manufacturing Footprint: 10 facilities (6 for Finished Dosage Forms, 4 for Active Pharmaceutical Ingredients)
• Existing Approvals: Facilities approved by leading regulators, including USFDA and UK-MHRA

This EU GMP certification from the Malta Medicines Authority adds another feather to Indoco’s cap, affirming its relentless pursuit of excellence and quality in an increasingly competitive global pharmaceutical landscape. Investors and stakeholders can view this as a clear signal of the company’s strategic growth trajectory and its dedication to meeting international benchmarks.